Trial reportAmerican journal of ophthalmology2011
A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study.
Trial report in American journal of ophthalmology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 159 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
159 citing papers in PubMed, 3 syntheses or guidelines pooled it, 386 citations in OpenAlex.
- Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.Bone marrow transplantation · 2019Pooled it
- Neuroprotection for treatment of glaucoma in adults.The Cochrane database of systematic reviews · 2017Pooled it
- Neuroprotection for treatment of glaucoma in adults.The Cochrane database of systematic reviews · 2013Pooled it
- Impact of mono- or multitherapy on ocular surface health and quality of life after 5 years of follow-up in the Glaucoma Intensive Treatment Study (GITS).Acta ophthalmologica · 2026Trial
- Crossover Randomized Study of Pharmacologic Effects of Ripasudil-Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine.Advances in therapy · 2023Trial
- Comparative Assessment of Retinal Blood Flow Velocity Changes Following Brimonidine and Brinzolamide Administration Using Retinal Function Imaging.Translational vision science & technology · 2022Trial
- Trial
- Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial.Journal of glaucoma · 2020Trial
- Effect of palmitoylethanolamide on inner retinal function in glaucoma: a randomized, single blind, crossover, clinical trial by pattern-electroretinogram.Scientific reports · 2020Trial
- Effects of Brimonidine and Timolol on the Progression of Visual Field Defects in Open-angle Glaucoma: A Single-center Randomized Trial.Journal of glaucoma · 2019Trial
- Evaluation of Visual Field and Imaging Outcomes for Glaucoma Clinical Trials (An American Ophthalomological Society Thesis).Transactions of the American Ophthalmological Society · 2017Trial
- Real-time imaging of single neuronal cell apoptosis in patients with glaucoma.Brain : a journal of neurology · 2017Trial
- Efficacy of selective laser trabeculoplasty for normal tension glaucoma: 1 year results.BMC ophthalmology · 2015Trial
- Effect of brimonidine on retinal vascular autoregulation and short-term visual function in normal tension glaucoma.American journal of ophthalmology · 2014Trial
- Ocular Blood Flow in Eyes with Myopia and Glaucoma: From Pathophysiology to Clinical Implications.Journal of clinical medicine · 2026Review
- Real-world effectiveness and safety of a fixed-dose combination of 0.4% ripasudil and 0.1% brimonidine in the management of uveitic glaucoma.Japanese journal of ophthalmology · 2026Article
- Oxidative Stress in Glaucoma: From Pathogenic Mechanisms to Emerging Antioxidant Therapies.Antioxidants (Basel, Switzerland) · 2026Review
- Systemic α₂-agonist use and lower hazard of glaucoma compared with β-blockers: a cohort study.BMJ open ophthalmology · 2026Observational
- Risk of Glaucoma Progression in Patients Using a Calcium Channel Blocker: A Propensity-Matched Cohort Study.Investigative ophthalmology & visual science · 2026Article
- Retinal Ganglion Cell Degeneration in Glaucoma: Systematic Review.Bioengineering (Basel, Switzerland) · 2026Review
99 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the alpha2-adrenergic agonist brimonidine tartrate 0.2% to the beta-adrenergic antagonist timolol maleate 0.5% in preserving visual function in low-pressure glaucoma.
designRandomized, double-masked, multicenter clinical trial.
methodsExclusion criteria included untreated intraocular pressure (IOP) >21 mm Hg, visual field mean deviation worse than -16 decibels, or contraindications to study medications. Both eyes received twice-daily monotherapy randomized in blocks of 7 (4 brimonidine to 3 timolol). Standard automated perimetry and tonometry were performed at 4-month intervals. Main outcome measure was field progression in either eye, defined as the same 3 or more points with a negative slope ≥-1 dB/year at P<5%, on 3 consecutive tests, assessed by pointwise linear regression. Secondary outcome measures were progression based on glaucoma change probability maps (GCPM) of pattern deviation and the 3-omitting method for pointwise linear regression.
resultsNinety-nine patients were randomized to brimonidine and 79 to timolol. Mean (± SE) months of follow-up for all patients was 30.0 ± 2. Statistically fewer brimonidine-treated patients (9, 9.1%) had visual field progression by pointwise linear regression than timolol-treated patients (31, 39.2%, log-rank 12.4, P=.001). Mean treated IOP was similar for brimonidine- and timolol-treated patients at all time points. More brimonidine-treated (28, 28.3%) than timolol-treated (9, 11.4%) patients discontinued study participation because of drug-related adverse events (P=.008). Similar differences in progression were observed when analyzed by GCPM and the 3-omitting method.
conclusionLow-pressure glaucoma patients treated with brimonidine 0.2% who do not develop ocular allergy are less likely to have field progression than patients treated with timolol 0.5%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.